System USRD. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020.

Tonelli M. Wiebe N. Knoll G. et al.

Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes.

Am J Transplant. 11: 2093-2109Dew M.A. Switzer G.E. Goycoolea J.M. et al.

Does transplantation produce quality of life benefits? A quantitative analysis of the literature.

Transplantation. 64: 1261-1273Wolfe R.A. Ashby V.B. Milford E.L. et al.

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

N Engl J Med. 341: 1725-1730Feld J.J. Jacobson I.M. Hezode C. et al.

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

N Engl J Med. 373: 2599-2607Feld J.J. Moreno C. Trinh R. et al.

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.

J Hepatol. 64: 301-307Foster G.R. Afdhal N. Roberts S.K. et al.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

N Engl J Med. 373: 2608-2617Younossi Z.M. Stepanova M. Sulkowski M. et al.

Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.

Clin Infect Dis. 63: 1042-1048

Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Clin Infect Dis. 67: 1477-1492Heo N.Y. Mannalithara A. Kim D. Udompap P. Tan J.C. Kim W.R.

Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States.

Transplantation. 102: 454-460Scott D.R. Wong J.K. Spicer T.S. et al.

Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand.

Transplantation. 90: 1165-1171Batty Jr., D.S. Swanson S.J. Kirk A.D. Ko C.W. Agodoa L.Y. Abbott K.C.

Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival.

Am J Transplant. 1: 179-184Wei F. Liu J. Liu F. Hu H. Ren H. Hu P.

Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis.

PLoS One. 9e90611Kidney Disease: Improving Global O

KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.

Kidney Int Suppl. : S1-99Bucci J.R. Matsumoto C.S. Swanson S.J. et al.

Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation.

J Am Soc Nephrol. 13: 2974-2982Gupta G. Kang L. Yu J.W. et al.

Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data.

Clin Transplant. 31Dao A. Cuffy M. Kaiser T.E. et al.

Use of HCV Ab+/NAT- donors in HCV naive renal transplant recipients to expand the kidney donor pool.

Clin Transplant. 33e13598de Vera M.E. Volk M.L. Ncube Z. et al.

Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia.

Am J Transplant. 18: 2451-2456Bloom R.D. Sayer G. Fa K. Constantinescu S. Abt P. Reddy K.R.

Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list.

Am J Transplant. 5: 139-144Ryerson A.B. Schillie S. Barker L.K. Kupronis B.A. Wester C.

Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018.

MMWR - Morbidity & Mortality Weekly Report. 69: 399-404

Record Owner NLM. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States.

Rudd R.A. Aleshire N. Zibbell J.E. Gladden R.M.

Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.

MMWR Morb Mortal Wkly Rep. 64: 1378-1382Rudd R.A. Seth P. David F. Scholl L.

Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015.

MMWR Morb Mortal Wkly Rep. 65: 1445-1452Abara W.E. Collier M.G. Moorman A. et al.

Characteristics of Deceased Solid Organ Donors and Screening Results for Hepatitis B, C, and Human Immunodeficiency Viruses - United States, 2010-2017.

MMWR Morb Mortal Wkly Rep. 68: 61-66Durand C.M. Bowring M.G. Thomas A.G. et al.

The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study.

Ann Intern Med. 168: 702-711Goldberg D.S. Blumberg E. McCauley M. Abt P. Levine M.

Improving Organ Utilization to Help Overcome the Tragedies of the Opioid Epidemic.

Am J Transplant. 16: 2836-2841Ariyamuthu V.K. Sandikci B. AbdulRahim N. et al.

Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard.

Transpl Infect Dis. 22e13204Ariyamuthu V.K. Tanriover B.

Optimizing Utilization of Kidneys from Hepatitis C-Positive Kidney Donors.

Clin J Am Soc Nephrol. 16: 188-190

Effect of the Opioid Crisis on the Donor Pool for Kidney Transplantation: An Analysis of National Kidney Deceased Donor Trends from 2010-2016.

Am J Nephrol. 47: 84-93Potluri V.S. Goldberg D.S. Mohan S. et al.

National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys.

J Am Soc Nephrol. 30: 1939-1951Wang J.H. Gustafson S.K. Skeans M.A. et al.

OPTN/SRTR 2018 Annual Data Report: Hepatitis C.

Am J Transplant. 20: 542-568Bowring M.G. Shaffer A.A. Massie A.B. et al.

Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States.

Am J Transplant. 19: 2329-2341King K.L. Husain S.A. Mohan S.

Trends in Transplantation Center Use of Kidneys From Deceased Donors With Positive Hepatitis C Virus Nucleic Acid Testing.

Am J Kidney Dis. 76: 743-746Kling C.E. Perkins J.D. Landis C.S. Limaye A.P. Sibulesky L.

Utilization of Organs From Donors According to Hepatitis C Antibody and Nucleic Acid Testing Status: Time for Change.

Am J Transplant. 17: 2863-2868Reese P.P. Abt P.L. Blumberg E.A. Goldberg D.S.

Transplanting Hepatitis C-Positive Kidneys.

N Engl J Med. 373: 303-305Lentine K.L. Peipert J.D. Alhamad T. et al.

Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers.

Kidney360. 1: 1291-1299Eckman M.H. Woodle E.S. Thakar C.V. Alloway R.R. Sherman K.E.

Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.

Am J Kidney Dis. 75: 857-867Kadatz M. Klarenbach S. Gill J. Gill J.S.

Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients.

Am J Transplant. 18: 2457-2464Gupta G. Zhang Y. Carroll N.V. Sterling R.K.

Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy.

Am J Transplant. 18: 2496-2505Goldberg D.S. Abt P.L. Blumberg E.A. et al.

Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients.

N Engl J Med. 376: 2394-2395Durand C.M. Bowring M.G. Brown D.M. et al.

Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.

Ann Intern Med. 168: 533-540Molnar M.Z. Nair S. Cseprekal O. et al.

Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience.

Am J Transplant. 19: 3046-3057Kapila N. Menon K.V.N. Al-Khalloufi K. et al.

Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience.

Hepatology. 72: 32-41Sise M.E. Goldberg D.S. Kort J.J. et al.

Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.

J Am Soc Nephrol. 31: 2678-2687Friebus-Kardash J. Gackler A. Kribben A. et al.

Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.

Transpl Infect Dis. 21e13146Duerr M. Liefeldt L. Friedersdorff F. et al.

Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients.

J Clin Med. 10Feld J.J. Cypel M. Kumar D. et al.

Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study.

Lancet Gastroenterol Hepatol. 5: 649-657Gupta G. Yakubu I. Bhati C.S. et al.

Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients.

Am J Transplant. 20: 739-751Jandovitz N. Nair V. Grodstein E. et al.

Hepatitis C-positive donor to negative recipient kidney transplantation: A real-world experience.

Transpl Infect Dis. e13540Sise M.E. Strohbehn I.A. Chute D.F. et al.

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation.

Kidney Int Rep. 5: 459-467Terrault N.A. Burton J. Ghobrial M. et al.

Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.

Hepatology. Durand C.M. Barnaba B. Yu S. et al.

Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study.

Ann Intern Med. 174: 137-138Woolley A.E. Singh S.K. Goldberg H.J. et al.

Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.

N Engl J Med. 380: 1606-1617Reese P.P. Abt P.L. Blumberg E.A. et al.

Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.

Ann Intern Med. 169: 273-281Molnar M.Z. Azhar A. Tsujita M. et al.

Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes.

Am J Kidney Dis. 77: 739-747 e731Mazur R.D. Abt P.L. Blumberg E.A. et al.

Characterization of early hepatic injury in HCV-negative recipients of HCV-infected kidneys.

Clin Transplant. 33e13494Kapila N. Al-Khalloufi K. Bejarano P.A. Vanatta J.M. Zervos X.B.

Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: A unique complication in the DAA era.

Am J Transplant. 20: 600-605McCauley M. Mussell A. Goldberg D. et al.

Race, Risk, and Willingness of End-Stage Renal Disease Patients Without Hepatitis C Virus to Accept an HCV-Infected Kidney Transplant.

Transplantation. 102: e163-e170Daloul R. Pesavento T. Michaels A.

Expanding the use of HCV infected organs and the challenge of third-party payers.

Am J Transplant. 20: 1463-1464Torabi J. Rocca J.P. Ajaimy M. et al.

Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients.

Transpl Infect Dis. : e13449Bethea E. Arvind A. Gustafson J. et al.

Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning.

Am J Transplant. 20: 1619-1628Israni A.K. Salkowski N. Gustafson S. et al.

New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes.

J Am Soc Nephrol. 25: 1842-1848Rao P.S. Schaubel D.E. Guidinger M.K. et al.

A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index.

Transplantation. 88: 231-236La Hoz R.M. Sandikci B. Ariyamuthu V.K. Tanriover B.

Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.

Am J Transplant. 19: 3058-3070Cannon R.M. Locke J.E. Orandi B.J. et al.

Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?.

Transplantation. 104: 1215-1228Sibulesky L. Kling C.E. Limaye A.P. Johnson C.K.

Is Kidney Donor Profile Index (KDPI) Valid for Hepatitis C Aviremic Kidneys?.

Ann Transplant. 22: 663-664Yazawa M. Balaraman V. Tsujita M. et al.

Donor hepatitis C antibody positivity misclassifies kidney donor profile index in non-hepatitis C-infected donors: time to revise the kidney donor profile index - a retrospective cohort study.

Transpl Int. 33: 1732-1744Sibulesky L. Kling C.E. Blosser C. et al.

Are we underestimating the quality of aviremic hepatitis C-positive kidneys? Time to reconsider.

Am J Transplant. 18: 2465-2472